March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Standardized Automated Perimetry And OCT Parameters Correlation In Patients With Dominant Optic Atrophy Due To Opa1 Mutation
Author Affiliations & Notes
  • Giacinto Triolo
    Department of Ophthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Stefania Bianchi Marzoli
    Ophthalmology, Scientific Inst San Raffaele Univ Vita-Salute, Milano, Italy
  • Maria Lucia Cascavilla
    Scientific Inst San Raffaele, Milano, Italy
  • Lisa Melzi
    Department of Ophthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Luisa M. Pierro
    Department of Ophthalmology, Scientific Institute San Raffaele, Milan, Italy
  • Francesco Bandello
    Ophthalmology, Univ Vita Salute-Scient Inst San Raffaele, Milan, Italy
  • Footnotes
    Commercial Relationships  Giacinto Triolo, None; Stefania Bianchi Marzoli, None; Maria Lucia Cascavilla, None; Lisa Melzi, None; Luisa M. Pierro, None; Francesco Bandello, Alcon (C), Alimera (C), Allergan (C), Bauch & Lomb (C), Bayer (C), Genentech (C), Novartis (C), Pfizer (C), Theà (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3926. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Giacinto Triolo, Stefania Bianchi Marzoli, Maria Lucia Cascavilla, Lisa Melzi, Luisa M. Pierro, Francesco Bandello; Standardized Automated Perimetry And OCT Parameters Correlation In Patients With Dominant Optic Atrophy Due To Opa1 Mutation. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3926.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To quantify the functional and structural optic nerve damage in patients affected by Dominant Optic Atrophy (DOA) by using Standardized Automated Perimetry (SAP) and Time and Spectral Domain OCT (TD and SD OCT); to compare TD and SD OCT axonal and ganglion cell loss within the peripapillary and the macular region; to correlate visual field loss with TD and SD OCT parameters

Methods: : We enrolled 20 patients (38 eyes) with DOA due to genetically confirmed OPA1 mutation (mean age 34 years; range 10-76). SAP was performed with Humphrey Zeiss 30-2 and 10-2 SITA Standard Perimetry (MD and PSD values were used for statistical comparisons). OCT data were acquired by TD Stratus and SD RTVue-100

Results: : Abnormal 30-2 SAP was found in 47% of the eyes. In all patients with normal 30-2 (53%), 10-2 SAP revealed abnormalities. TD-OCT showed: reduced average peripapillary RNFL thickness (RNFLT) in 95% of the eyes; reduced temporal RNFLT, normal central macular thickness (CMT) and normal total macular volume (TMV) in all eyes. SD-OCT showed: reduced average RNFLT in 92% of the eyes; reduced temporal RNFLT in all cases; reduced Ganglion Cell Complex Thickness (GCCT) in 84% of the eyes; normal CMT values in all eyes. Statistically significant correlations were found between both 30-2 and 10-2 SAP and TD OCT average and temporal RNFLT; between 30-2 SAP and SD OCT average RNFLT; between both TD and SD OCT average RNFLT; between average RNFLT and TMV measured with both TD and SD OCT; and between CMT values with both TD and SD OCT. Non statistically significant correlations were found between GCCT and 30-2 SAP, 10-2 SAP and Stratus and RTVue-100 RNFLT measurements

Conclusions: : In DOA, 30-2 SAP can be normal despite optic nerve damage which can be instead detected by 10-2 and can be related to disease duration. RNFLT measurements obtained with TD OCT better demonstrate mild optic nerve atrophy; while SD OCT can be used to detect GCCT reduction despite normal RNFLT. These results suggest that TD OCT and 10-2 SAP may be used to evaluate mild optic nerve damage in DOA

Keywords: neuro-ophthalmology: optic nerve • optic nerve • visual fields 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×